Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

1.63
Delayed Data
As of 4:04pm ET
 -0.04 / -2.40%
Today’s Change
1.26
Today|||52-Week Range
6.86
-56.53%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$225.0M

Company Description

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Contact Information

Adaptimmune Therapeutics Plc
60 Jubilee Avenue
Abingdon Oxfordshire OX14 4RX
P:441235430000
Investor Relations:
(215) 825-9310

Employees

Shareholders

Other institutional56.59%
Individual stakeholders14.02%
Mutual fund holders10.63%

Top Executives

Adrian RawcliffeChief Executive Officer & Director
William C. BertrandChief Operating Officer
Gavin WoodChief Financial Officer
Joanna BrewerChief Scientific Officer
Helena Katrina Tayton-MartinChief Business Officer